Patients
WELCOME TO A
NEW CHAPTER IN
BRAIN CANCER TREATMENT
01
We understand...
…how overwhelming a Glioblastoma diagnosis can be. Our mission is to provide patients and families with access to the most promising clinical trial to date for GBM: Sonodynamic Therapy. We are aiming to enrol by the end of 2026.
We are here for you: to answer your questions, address your concerns, and walk beside you throughout your SDT journey.
02
Why does our SDT matter?
We founded CureGBM because our father died of GBM in 2021; we know how it feels to be ‘helpless’. As a legacy to him, we’ve been working since then to bring a novel treatment to Europe for Glioblastoma patients.
Early clinical trials clearly show SDT is the single best option for GBM patients. We kick-off SDT trials in Europe in 2026, bringing hope to those who’ve seen no improvement in the current ‘Standard of Care’ (brain surgery, chemo- radio-therapy).
03
How we Support YOU through your SDT journey
- Personalized discussions and planning the next steps; every patient’s tumour and journey are unique
- Access our SDT Trial. Explore a promising new treatment beyond standard care, with no known side effects (within eligibility criteria)
- From care coordination to emotional support, we’re here to help you navigate your journey with confidence
- Your 3-monthly MRI scans would be used along with a single CT scan to plan your treatment; this ensures you have minimal disruption to your therapeutic journey
04
Clinical Trials of SDT: Expanding Possibilities
Our planned trials are designed to offer hope and options for patients with recurrent Glioblastoma. Participation includes:
- Cutting-edge therapies not yet widely available
- Close monitoring by experienced clinical teams
- Opportunities to contribute to future breakthroughs
- If ineligible, we’ll help you apply for compassionate treatment
05
Eligibility & Enrollment
- Open to adults with confirmed recurrent Glioblastoma
- Requires recent imaging and pathology reports
- Eligibility is based on pre-screening criteria (e.g. concurrent health conditions, brain scan analysis and blood results etc.)
More detailed eligibility criteria are listed here
06
Clinical Trial Specifics
- Our Phase 1 Safety Trial will be based in Bern, Switzerland (aiming to start late 2026)
- The Phase 2 Efficacy Trial will likely be in Bern, Milan, and London (tbc)
- We will support with logistic coordination of travel and accommodation, as required
07
Support Every Step of the Way
We can connect you with:
- Dedicated care coordinators
- Psychological counselling
- Financial and insurance guidance
08
Ready to Take the Next Step?
Whether you’re newly diagnosed or seeking new options, we’re here to help.
- Contact us here
- Travel and accommodation assistance
